Virchows Archiv

, Volume 462, Issue 6, pp 603–607 | Cite as

HER2 protein expression and HER2 gene amplification are infrequent in small intestinal carcinomas

  • Mi Jin Gu
  • Seung-Mo Hong
  • Soo Jin Jung
  • The Korean Small Intestinal Cancer Study Group
Original Article

Abstract

Human epidermal growth factor receptor 2 (HER2/neu) gene amplification and HER2 protein overexpression have been associated with clinicopathological parameters and clinical outcome in many carcinomas. The aim of this study was to evaluate the frequency and prognostic impact of HER2 protein overexpression and gene amplification in small intestinal carcinoma (SIC). We performed immunohistochemistry (IHC) for HER2 protein and silver in situ hybridization for the HER2 gene in a total of 194 SICs. A total of 184 cases (94.8 %) were IHC 0 and 6 cases (3.1 %) were IHC 1+ with no gene amplification. HER2 protein overexpression (IHC 3+) with concordant gene amplification was detected in four cases (2.1 %), using the American Society of Clinical Oncology–College of American Pathologists guidelines for breast cancer. HER2 gene amplification was observed in an equivocal (IHC 2+) metastatic tumor in lymph node. No significant correlation was observed between HER2 status and clinicopathological parameters. Although HER2 protein overexpression and amplification were rare and did not correlate with clinicopathological parameters, further studies will be necessary to answer the question as to whether adjuvant therapy targeting the HER2 receptor might improve outcome in patients with a SIC with HER2 gene amplification and protein overexpression.

Keywords

Small intestine Carcinoma Human epidermal growth factor receptor 2 Immunohistochemistry Silver in situ hybridization 

Notes

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Hechtman JF, Polydorides AD (2012) HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. Arch Pathol Lab Med 136:691–697PubMedCrossRefGoogle Scholar
  2. 2.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182PubMedCrossRefGoogle Scholar
  3. 3.
    Chua TC, Merrett ND (2012) Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer 130:2845–2856PubMedCrossRefGoogle Scholar
  4. 4.
    Dang HZ, Yu Y, Jiao SC (2012) Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol 18:2402–2407PubMedCrossRefGoogle Scholar
  5. 5.
    Schillaci R, Guzman P, Cayrol F, Beguelin W, Diaz Flaque MC, Proietti CJ, Pineda V, Palazzi J, Frahm I, Charreau EH, Maronna E, Roa JC, Elizalde PV (2012) Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer 12:74. doi: 10.1186/1471-2407-12-74 PubMedCrossRefGoogle Scholar
  6. 6.
    Chan OT, Chen ZM, Chung F, Kawachi K, Phan DC, Himmelfarb E, Lin F, Perry A, Wang HL (2010) Lack of HER2 overexpression and amplification in small intestinal adenocarcinoma. Am J Clin Pathol 134:880–885PubMedCrossRefGoogle Scholar
  7. 7.
    Jorgensen JT, Hersom M (2012) HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J Cancer 3:137–144PubMedCrossRefGoogle Scholar
  8. 8.
    Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 98:833–837PubMedCrossRefGoogle Scholar
  9. 9.
    Schuell B, Gruenberger T, Scheithauer W, Zielinski C, Wrba F (2006) HER 2/neu protein expression in colorectal cancer. BMC Cancer 6:123. doi: 10.1186/1471-2407-6-123 PubMedCrossRefGoogle Scholar
  10. 10.
    Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H (2010) Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102:144–150PubMedCrossRefGoogle Scholar
  11. 11.
    Zhu L, Kim K, Domenico DR, Appert HE, Howard JM (1996) Adenocarcinoma of duodenum and ampulla of Vater: clinicopathology study and expression of p53, c-neu, TGF-alpha, CEA, and EMA. J Surg Oncol 61:100–105PubMedCrossRefGoogle Scholar
  12. 12.
    Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132PubMedCrossRefGoogle Scholar
  13. 13.
    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, ToGA Trial Investigators (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Mi Jin Gu
    • 1
  • Seung-Mo Hong
    • 2
  • Soo Jin Jung
    • 3
  • The Korean Small Intestinal Cancer Study Group
  1. 1.Department of PathologyYeungnam University College of MedicineDaeguRepublic of Korea
  2. 2.Department of Pathology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulRepublic of Korea
  3. 3.Department of PathologyInje University College of MedicineBusanRepublic of Korea

Personalised recommendations